Results 131 to 140 of about 287,893 (307)

Intraperitoneal CAR T-cell therapy for peritoneal carcinomatosis from gastroesophageal cancer: preclinical investigations to a phase I clinical trial (NCT06623396)

Journal for ImmunoTherapy of Cancer
Peritoneal carcinomatosis is a frequent metastatic condition in gastroesophageal cancer and is associated with poor prognosis and limited therapeutic options.
Geoffrey Ku, Prasad S Adusumilli, David Restle, Kyohei Misawa, Alfredo Amador-Molina, Srijita Banerjee   +5 more
doaj   +1 more source

Efficacy and safety of anti-programmed cell death protein 1 antibody combination therapy in patients with advanced experienced epidermal growth factor receptor-tyrosine kinase inhibitor-resistant lung adenocarcinoma: a retrospective cohort study [PDF]

, 2023
Chang Wan, Yiruo Zhang, Pingping Liu, Xinkuan Mei, Gang Cheng, Jingdan Pang, Sheng Chen, Jianping Xu, Jyoti Malhotra, Hesheng Qian, Yingying Du   +10 more
openalex   +1 more source

Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients. [PDF]

, 2019
BackgroundWe previously reported the results of a multicentric prospective randomized trial of chemo-refractory metastatic breast cancer patients testing the efficacy of two doses of TGFβ blockade during radiotherapy.
Demaria, Sandra, Dixit, Neha, Evensen, Erik, Formenti, Silvia C, Goldberg, Judith D, Hawtin, Rachael E, Lee, Percy, Li, Xiaochun, McBride, William H, Schaue, Dörthe, Vanpouille-Box, Claire   +10 more
core   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Bullous pemphigoid secondary to bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1

JAAD Case Reports, 2021
Claire J. Wiggins, BS, Van K. Morris, MD, Natasha K. Klimas, MD, Priyadharsini Nagarajan, MD, PhD, Jonathan L. Curry, MD, Kristen N. Richards, MD   +5 more
doaj   +1 more source

Extracellular acidity in tumor tissue upregulates programmed cell death ligand 1 expression on tumor cells via proton‐sensing G protein‐coupled receptors [PDF]

, 2021
Daichi Mori, Takahiro Tsujikawa, Yoichiro Sugiyama, Shin‐ichiro Kotani, Shinya Fuse, Gaku Ohmura, Akihito Arai, Tsutomu Kawaguchi, Shigeru Hirano, Osam Mazda, Tsunao Kishida   +10 more
openalex   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Role of Programmed Cell Death Protein-1 and Lymphocyte Specific Protein Tyrosine Kinase in the Aryl Hydrocarbon Receptor- Mediated Impairment of the IgM Response in Human CD5+ Innate-Like B Cells [PDF]

, 2022
Jiajun Zhou, Lance K. Blevins, Robert B. Crawford, Norbert E. Kaminski   +3 more
openalex   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source